Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Active:	No
Cancer Type:	Prostate Cancer	NCT ID:	NCT05177770
Trial Phases:	Phase II	Protocol IDs:	SRF617-201 (primary) NCI-2022-02287
Eligibility:	18 Years and older, Male	Study Type:	Treatment
Study Sponsor:	Surface Oncology
NCI Full Details:	http://clinicaltrials.gov/show/NCT05177770

Summary

This trial will look at the safety and preliminary efficacy of SRF617 in combination with
etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate
cancer (mCRPC).

Objectives

This is a phase 2, open-label, safety and preliminary efficacy trial in patients with mCRPC
using the combination of SRF617, etrumadenant (AB928), and zimberelimab (AB122).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.